Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023” report has been added to ResearchAndMarkets.com’s offering.

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.

Chapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.

The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

Key benefits

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits:

In-depth understanding of joint venture partnering deal trends since 2016, with real life case studies

Comprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release

Comprehensive access to actual joint venture contracts entered into by the world’s life science companies

Insight into the terms included in a joint venture agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes:

Trends in joint venture dealmaking in the biopharma industry since 2016

Case studies of real-life joint venture deals

Comprehensive listing of joint venture deals since 2016

Access to joint venture contract documents

The leading joint venture deals by value since 2016

Most active joint venture dealmakers since 2016

The leading joint venture partnering resources

In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by:

Company A-Z

Headline value

Therapeutic area

Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals.

Companies Mentioned

3SBio

1717 Life Science Ventures

A*STAR Agency for Science

Technology and Research

A*STAR Institute of Microelectronics (IME)

A*STAR’ Institute of Molecular and Cell Biology

A2A Pharmaceuticals

AAP Implantate AG

Abbott Laboratories

Abbvie

Abilita Bio

ABIVAX

Abzena

Accellix

Accuray

Acnos Pharma

Adept Neuro

Adisseo

Advanced Prenatal Therapeutics

Advanced Technologies Solutions

Aequus Pharmaceuticals

Agilis Biotherapeutics

AgonOx

AirWare Labs

Aitbiotech

Akers Biosciences

AKESOgen

Aleafia Health

Aleva Neurotherapeutics

Allied-Bristol Life Sciences

Allied Minds

Ally Bridge Group

Altus Formulation

Alzheimer’s Association

Alzheimer’s Research UK

Amarantus BioSciences

Amendia

American Diabetes Association

AmerisourceBergen

Amunix

Amyris

AnaBios

Anokion

Antitope

Antoxerene

Apax Partners

Aphria

Arbele

Arbutus

ARCH Personalized Medicine Initiative

Aridis Pharmaceuticals

Aruvant Sciences

Arvinas

Ascendance Biotechnology

Ascendis Pharma

Asklepios Biopharmaceutical

Aslan Pharma

Astellas Pharma

AstraZeneca

ATAI Life Sciences

Athenex

ATL Technology

Atomwise

Atrapos Therapeutics

Atropos Therapeutics

Auramedi Farmaceutica

Autobio Diagnostics

AUT Roche Diagnostics Laboratory

AUT University

Auxly Cannabis Group

Avacta

Avactis Biosciences

Avalon GloboCare

Avivagen

Avvinity Therapeutics

Axis Therapeutics

Bain Capital

Baxter International

Bayer

Baylor College of Medicine

Baylor Miraca Genetics Laboratories

B Braun

B Braun CeGaT

Beckley Canopy Therapeutics

Beckley Foundation

Becton Dickinson

BeiGene

Beijing Genomics Institute (BGI)

Beijing Leadman Biochemistry

Berry Genomics

Betaliq

BevCanna

BGI Tech Solutions

BHB Therapeutics

Bill and Melinda Gates Foundation

Bio-Techne

BioAmber

Biodist

Biodyne USA

BioFields

Biogen

Biohealth Innovation

BioHeart

BioLife Solutions

BioLight

BiolineRX

biologistex CCM

BioMed X Innovation Center

Biomerics

BioMotiv

BioPharma Services

Blackstone

Blockshine Technology

Bloomage BioTechnology

Bloom Burton

BLP Management

Blueberries Medical

Boehringer Ingelheim

Breakthrough Diagnostics

Brigham and Women’s Hospital

Bristol-Myers Squibb

Broad Institute

Buchang Pharmaceutical

Buck Institute for Age Research

Bukwang Pharmaceuticals

Button Capital

Calysta Energy

Cancer Research Technology

Cannabics Pharmaceuticals

Cannabis Biocare

Cannabis Therapeutics

CannAmerica Brands

CannaRoyalty

Canopy Health Innovations

Capna Intellectual

Capnia

Cardio3 Biosciences Asia Holdings

Casebia Therapeutics

Catapult Therapy TCR

CB2 Therapeutics

CBDerma Technology

CBDistribution

Cedar Gate Technologies

CeGaT

Cell Therapy Catapult

Celyad

Centauri Therapeutics

Centene

Center for Genetic Engineering and Biotechnology (Cuba)

Centre for Commercialization of Regenerative Medicine (CCRM)

Centro de Inmunolgia Molecular

Cerevel Therapeutics

Cesca Therapeutics

Chan Soon-Shiong Institute of Molecular Medicine

ChemAxon

Children’s Medical Research Institute

Chimera Biotec

China-Israel Biological Technology

China-Singapore Guangzhou Knowledge City

China Isotope And Radiation

Chinese Academy of Science

Chinese Future Industry Investment Fund

Chongqing PSK-Health Sci-tech Development

Cincinnati Children’s Hospital Medical Center

City of Hope

CJ CheilJedang

ClearPath

Cloaked Therapeutics

Co-Diagnostics

Cohen Veterans Bioscience

Cold Spring Harbor

Colibri Heart Valve

Collagen Solutions Plc

Columbus Venture Partners

Concentrics Research

Consortium AI

Corestone Biosciences

Cornerstone Animal Health

Corning

Covenant Animal Health Partners

Cre8ive

CRISPR Therapeutics

CureCell

Cyclica

CytoBioscience

Cytotheryx

Cytovant Sciences

Daewoong Pharmaceutical

Dance Biopharm

Dasman Diabetes Institute

David Snow

Deerfield Management

DemeRx

Demetra

Denka

Denka-KEW Genomics

DepYmed

DIAN Diagnostics

Diavax Biosciences

Dixi

Dizal Pharmaceutical

DolCas-Tenshi Bioceuticals

DolCas Biotech

Dona Blanca

Dongbao

Dr. Walter Bell

Duke-NUS Graduate Medical School Singapore

Eastar Industries

Eastern Capital

Easton Pharmaceuticals

eCardio Diagnostics

Eddingpharm

Eden BioCell

Elanix Biotechnologies

Elevar Therapeutics

Eli Lilly

EMD Millipore

EMD Serono

Emergence Therapeutics

EmoCellix

Emory University

Emosis

Enigma Diagnostics

Enova Illumination

Entheogenix Biosciences

ERS Genomics

Evotec

ExCellThera

Exemplar Genetics

Facebook

Faes Farma

Faxian Therapeutics

Fedecore

Fedora Pharmaceuticals

FerGene

Ferring Pharmaceuticals

FJ Pharma

Flexpoint Ford

Flow Pharma

Fonterra

Food and Drug Administration (FDA)

FORMA Therapeutics

Fortress Biotech

Fosun Pharmaceutical

FoxBio

Fox Chase Cancer Center

Fraunhofer Institute for Microelectronic Circuits and Systems

Frazier Healthcare Ventures

Fresenius Kabi Pharmaceuticals

Frontage Laboratories

FSD Pharma

Futura Medical

Fuzionaire Diagnostics

Fuzionaire Radioisotope Technologies

G-treeBNT

Galectin Sciences

Galectin Therapeutics

Galvani Bioelectronics

Gauss Surgical

Genentech

Gene Therapy Research Institution

Genetic Technologies

Genevant Sciences

Genome Institute of Singapore

Genomix Scientific

Gentag

GeoVax

German Research Center for Artificial Intelligence

Gerresheimer

GHO Capital

Ginkgo BioWorks

GlaxoSmithKline

For more information about this report visit https://www.researchandmarkets.com/r/laae8e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.